International Scientific Publications
© 2007-2026 Science Events Ltd
Terms of Use  ·  Privacy Policy
Language English French Polish Romanian Bulgarian
Conference room
Materials, Methods & Technologies 2026, 28th International Conference
13-16 August, Burgas, Bulgaria
Call for Papers

Materials, Methods & Technologies, Volume 7, 2013

EFFECT OF THE MAIN NON-BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
Oleg Iaremenko, Ganna Mykytenko, Dmitro Fedkov
Pages: 421-431
Published: 1 Jan 2013
Views: 56
Abstract: In this clinical study, the effect of methotrexate (MTX), leflunomide (LF), sulfasalazine (SS) and the combination of disease modifying antirheumatic drugs (DMARDs) on radiological progression in patients with very early, early and advanced rheumatoid arthritis (RA) was determined. It was found that the effectiveness of all variants of DMARD therapy in very early and early RA is equal, while in advanced RA, LF and CBT are significantly superior to MTX and SS. The most important determinants of radiological progression of very early RA are level of antibodies to cyclic citrullinated peptide (anti-CCP) and total radiographic score, early RA - the presence of anti-CCP and total radiographic score, advanced RA - erosion score, level of anti-CCP, elevated levels of CRP and ESR value.
Keywords: rheumatoid arthritis, disease duration, disease modifying antirheumatic drugs, radiological progression
Cite this article: Oleg Iaremenko, Ganna Mykytenko, Dmitro Fedkov. EFFECT OF THE MAIN NON-BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS. Journal of International Scientific Publications: Materials, Methods & Technologies 7, 421-431 (2013). https://www.scientific-publications.net/en/article/1003124/
Back to the contents of the volume

Submit Feedback

We value your input! Use this form to report any concerns or provide feedback on our published articles. All submissions will be kept confidential.

By using this site you agree to our Privacy Policy and Terms of Use. We use cookies, including for analytics, personalisation, and ads.